Clinically practiced and commercially viable nanobio engineered analytical methods for COVID-19 diagnosis

Show simple item record

dc.contributor.author Mahapatra, S.
dc.contributor.author Chandra, P.
dc.date.accessioned 2020-11-20T09:53:17Z
dc.date.available 2020-11-20T09:53:17Z
dc.date.issued 2020-10-01
dc.identifier.issn 09565663
dc.identifier.uri http://localhost:8080/xmlui/handle/123456789/956
dc.description.abstract The recent outbreak of the coronavirus disease (COVID-19) has left the world clueless. As the WHO declares this new contagion as a pandemic on the 11th of March 2020, the alarming rate of the spawn of the disease in such a short period has disarranged the globe. Standing against this situation researchers are strenuously searching for the key traits responsible for this pandemic. As knowledge regarding the dynamics and host-path interaction of COVID-19 causing Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is currently unknown, the formulation of strategies concerning antiviral treatment, vaccination, and epidemiological control stands crucial. Before designing adequate therapeutic strategies, it is extremely essential to diagnose the disease at the outset as early detection can have a greater impact on building health system capacity. Hence, a comprehensive review of strategies for COVID-19 diagnosis is essential in this existing global situation. In this review, sequentially, we have provided the clinical details along with genetic and proteomic biomarkers related to COVID-19. The article systematically enlightens a clear overview of the clinically adopted techniques for the detection of COVID-19 including oligonucleotide-based molecular detection, Point-of-Care immunodiagnostics, radiographical analysis/sensing system, and newly developed biosensing prototypes having commercial viability. The commercial kits/analytical methods based-sensing strategies have also been tabulated categorically. The critical insights on the developer, commercial brand name, detection methods, technical operational details, detection time, clinical specimen, status, the limit of detection/detection ability have been discussed comprehensively. We believe that this review may provide scientists, clinicians and healthcare manufacturers valuable information regarding the most recent developments/approaches towards COVID-19 diagnosis. © 2020 Elsevier B.V. en_US
dc.description.sponsorship Banaras Hindu University en_US
dc.language.iso en_US en_US
dc.publisher Elsevier Ltd en_US
dc.relation.ispartofseries Biosensors and Bioelectronics;Vol. 165
dc.subject COVID-19 en_US
dc.subject SARS-CoV-2 en_US
dc.subject Clinical diagnosis en_US
dc.subject RT-PCR en_US
dc.subject Immunoassay en_US
dc.subject Serological tests en_US
dc.subject Point of care en_US
dc.title Clinically practiced and commercially viable nanobio engineered analytical methods for COVID-19 diagnosis en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search in IDR


Advanced Search

Browse

My Account